Lancet. 1981 Mar 28;1(8222):681-6.
A controlled trial of long term domiciliary oxygen therapy has been carried out in three centres in the U.K. The 87 patients, all under 70 years of age, who took part had chronic bronchitis or emphysema with irreversible airways obstruction, severe arterial hypoxaemia, carbon dioxide retention, and a history of congestive heart failure. The patients were randomised to oxygen therapy (treated) or no oxygen (controls). Oxygen was given by nasal prongs for at least 15 h daily, usually at 2 1/min. The two groups were well matched, both clinically and in terms of lung function and other laboratory findings. 19 of the 42 oxygen treated patients died in the five years of survival follow-up compared with 30 out of 45 controls: in the 66 men in this trial the survival advantage of oxygen did not emerge until 500 days had elapsed. Survival for the 12 female controls was surprisingly poor, 8 of them being dead at 3 years. Mortality was not easy to predict, though a summation of arterial carbon dioxide tension and red cell mass was helpful. Neither time spent in hospital because of exacerbations of respiratory failure nor work attendance were affected by oxygen therapy, but these patients were very ill at the start of the trial and many had already retired on grounds of age or ill-health. Physiological measurements suggested that oxygen did not slow the progress of respiratory failure in those who died early. However, in longer term survivors on oxygen, arterial oxygenation did seem to stop deterioration.
英国三个中心开展了一项长期家庭氧疗对照试验。参与试验的87名患者均年龄在70岁以下,患有慢性支气管炎或肺气肿,伴有不可逆的气道阻塞、严重动脉血氧不足、二氧化碳潴留以及充血性心力衰竭病史。患者被随机分为氧疗组(治疗组)或无氧组(对照组)。通过鼻导管每天至少吸氧15小时,通常为每分钟2升。两组在临床、肺功能及其他实验室检查结果方面匹配良好。在5年的生存随访中,42名接受氧疗的患者中有19人死亡,而45名对照组患者中有30人死亡:在该试验的66名男性中,直到500天后氧疗的生存优势才显现出来。12名女性对照组患者的生存率出奇地低,其中8人在3年时死亡。死亡率不易预测,不过动脉血二氧化碳分压与红细胞总量的总和有一定帮助。因呼吸衰竭加重而住院的时间及工作出勤率均未受氧疗影响,但这些患者在试验开始时病情就很重,许多人已因年龄或健康原因退休。生理测量结果表明,氧疗并未减缓早期死亡患者呼吸衰竭的进展。然而,在长期接受氧疗的存活者中,动脉氧合情况似乎确实停止了恶化。